Presentation is loading. Please wait.

Presentation is loading. Please wait.

Additional Slides - DA. Universal Screening Severe NHB (≥ X* mg/dL) No NHB Clinical Assessment/ Current Practice Severe NHB (≥ X* mg/dL) No NHB US Newborn.

Published byRodger Bradford Modified over 8 years ago

Similar presentations

Presentation on theme: "Additional Slides - DA. Universal Screening Severe NHB (≥ X* mg/dL) No NHB Clinical Assessment/ Current Practice Severe NHB (≥ X* mg/dL) No NHB US Newborn."— Presentation transcript:

1 Additional Slides - DA

2 Universal Screening Severe NHB (≥ X* mg/dL) No NHB Clinical Assessment/ Current Practice Severe NHB (≥ X* mg/dL) No NHB US Newborn Cohort CBE No CBE CBE No CBE Model Schematic *X = bilirubin level of 25 mg/dL or 30 mg/dL NHB = neonatal hyperbilirubinemia

3 Table 5. Projected Cases of CBE Averted US Newborn Cohort Incidence of CBE per 100,000 Projected Cases of CBE Impact of Screening* Projected Cases of CBE Averted 4,000,0000.5200.4228 4,000,0000.5200.72615 4,000,0001.0400.42217 4,000,0001.0400.72629 CBE = Chronic bilirubin encephalopathy *Proportion of cases averted

Download ppt "Additional Slides - DA. Universal Screening Severe NHB (≥ X* mg/dL) No NHB Clinical Assessment/ Current Practice Severe NHB (≥ X* mg/dL) No NHB US Newborn."

Similar presentations

Considerations for the Neonate Delivered at Home Susan J Dulkerian, MD Director of Nurseries, Mercy Medical Center Fetus and Newborn Subcommitee Chair.

Considerations for the Neonate Delivered at Home Susan J Dulkerian, MD Director of Nurseries, Mercy Medical Center Fetus and Newborn Subcommitee Chair.
Slide 1Fig. 2.1a, p.25. Slide 2Fig. 2.1b, p.25 Slide 3Table 2.1, p.25.

Slide 1Fig. 2.1a, p.25. Slide 2Fig. 2.1b, p.25 Slide 3Table 2.1, p.25.
OVERVIEW OF AMINO ACID METABOLISM ENVIRONMENT ORGANISM Ingested protein Bio- synthesis Protein AMINO ACIDS Nitrogen Carbon skeletons Urea Degradation (required)

OVERVIEW OF AMINO ACID METABOLISM ENVIRONMENT ORGANISM Ingested protein Bio- synthesis Protein AMINO ACIDS Nitrogen Carbon skeletons Urea Degradation (required)
Slide 1Fig. 22.1, p.669. Slide 2Fig. 22.3, p.670.

Slide 1Fig. 22.1, p.669. Slide 2Fig. 22.3, p.670.
Slide 1Fig. 17.1, p.513. Slide 2Table 17.1, p.514.

Slide 1Fig. 17.1, p.513. Slide 2Table 17.1, p.514.
Slide 1Fig. 11.1, p.337. Slide 2Fig. 11.2, p.338.

Slide 1Fig. 11.1, p.337. Slide 2Fig. 11.2, p.338.
Slide 1Fig. 19.1, p. 582. Slide 2Fig. 19.2, p. 583.

Slide 1Fig. 19.1, p Slide 2Fig. 19.2, p. 583.
Slide 1Fig. 21.1, p.641. Slide 2Fig. 21.2, p.642.

Slide 1Fig. 21.1, p.641. Slide 2Fig. 21.2, p.642.
Slide 1Fig. 10.1, p.293. Slide 2Fig. 10.1a, p.293.

Slide 1Fig. 10.1, p.293. Slide 2Fig. 10.1a, p.293.
Hyperbilirubinemia: Discussion Alexis Thompson, MD Catherine Wicklund, MS, CGC.

Hyperbilirubinemia: Discussion Alexis Thompson, MD Catherine Wicklund, MS, CGC.
Slide 1Fig. 5.1, p.113. Slide 2Fig. 5.1a, p.113 Slide 3Fig. 5.1b, p.113.

Slide 1Fig. 5.1, p.113. Slide 2Fig. 5.1a, p.113 Slide 3Fig. 5.1b, p.113.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Total Serum Bilirubin Levels at or Above the ETT Wu YW, Kuzniewicz MW, Wickremasinghe.

Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Total Serum Bilirubin Levels at or Above the ETT Wu YW, Kuzniewicz MW, Wickremasinghe.
1 times table 2 times table 3 times table 4 times table 5 times table

1 times table 2 times table 3 times table 4 times table 5 times table
275 BCH Miss Tahani Al-Shehri

275 BCH Miss Tahani Al-Shehri
Universal Predischarge Screening for Neonatal Hyperbilirubinemia Report from Evidence Review Secretary's Advisory Committee on Heritable Disorders in Newborns.

Universal Predischarge Screening for Neonatal Hyperbilirubinemia Report from Evidence Review Secretary's Advisory Committee on Heritable Disorders in Newborns.
Neonatal Jaundice Hyperbilirubinemia Fred Hill, MA, RRT.

Neonatal Jaundice Hyperbilirubinemia Fred Hill, MA, RRT.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.

Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Dr.Abdulaziz Alsoumali Intern Alyamamh hospital Pediatric rotation

Dr.Abdulaziz Alsoumali Intern Alyamamh hospital Pediatric rotation
Project/Product Title PI (and Co-PI) Affiliation August 10, 2012.

Project/Product Title PI (and Co-PI) Affiliation August 10, 2012.
Neonatal Hereditary Spherocytosis Prof. Rai Muhammad Asghar Head of Paediatric Department RMC & Allied Hospitals.

Neonatal Hereditary Spherocytosis Prof. Rai Muhammad Asghar Head of Paediatric Department RMC & Allied Hospitals.

Similar presentations

Ads by Google